Chime Biologics Relisted in the Hurun Global Gazelle Index 2022 Half-Year Report

On August 25, Chime Biologics was listed in the Hurun Global Gazelle Index 2022 Half-Year Report, released by Hurun Research Institute, for the second time. The report lists the high-growth companies founded after 2000 who are most likely to reach billion-dollar valuations of unicorn-level within the upcoming three years.

Hurun Research Institute listed 621 gazelle enterprises worldwide this time. Among 96 of them (18%) were listed within half a year and 163 were the new gazelles, which means one new gazelle was listed per day from the first half year.

Besides, 61 gazelle enterprises of last year were withdrew from the list due to the upgradation and 56 of them became the unicorn enterprises, 6 were removed due to downgrading. In the report, U.S. took the lead with 238 companies, with an increase number of 37 (18%), and China as the second with 200 companies, with 29 (17%) increase.

 About Gazelle Enterprises

Gazelle enterprises refer to the small and medium-sized companies that have crossed the “valley of death” since starting business and show a high growth trend after. These companies are like the gazelles, small in size but fast in growth, hence the name. Hurun Research Institute has been tracking the unicorn enterprises since 2017 and the gazelle enterprises from 2018. This is the second time the Institute released list of “Global gazelle enterprises”.

Chime Biologics was Relisted

Chime Biologics was listed among Gazelle enterprises for our compliance with international standards, quick response to market and customer demands, flexible one-stop CDMO services and continuous innovation to drive rapid growth. This is the second time Chime Biologics was listed on the list. In 2021, we were listed in the “Hurun Global Gazelle Index” when the list was first released by Hurun Research Institute.

 About Chime Biologics

Chime Biologics is a leading CDMO with the world’s first modular biopharmaceutical factory, KUBio. It empowers the entire biologics processes – from cell line development to commercial manufacturing. Chime Biologics provides one-stop CMC solutions to worldwide biomedical customers, relying on cell line development and advanced technology development from its Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan campus. We share a common goal to make cutting-edge biologics affordable and accessible to all patients globally, fulfilling its commitment to human health.